BioCentury | Apr 15, 2021
Emerging Company Profile

How SV-seeded Alchemab is searching for mAbs in super responders

Alchemab is mining the B cell repertoires of super responders, a strategy used for discovering potent mAbs to treat infectious diseases, and applying the same principle to difficult-to-treat cancer and...
BioCentury | Feb 2, 2021
Product Development

Feb. 2 Quick Takes: Immunovant tumbles as it pauses trial; plus BMS, Legend-J&J, Arcutis, Prothena, VBI, Travere, Concert and Adamas

Immunovant Inc. (NASDAQ:IMVT) lost 42% to $25.08 on Tuesday after announcing it was pausing trials of anti-FCRN mAb IMVT-1401 (batoclimab) due to elevated total cholesterol and LDL signals in the Phase IIb ASCEND GO-2 thyroid...
BioCentury | Jan 30, 2021
Distillery Therapeutics

Autophagy-activating gene therapy to treat recurrent HSV-2 infection

DISEASE CATEGORY: Infectious disease INDICATION: Herpes simplex virus (HSV); meningitis Gene therapies correcting ATG4A or MAP1LC3B2 mutations could treat recurrent HSV type 2 (HSV-2) meningitis in patients with the autophagy factor mutations. Autophagy activation by HSV-2...
BioCentury | Jan 29, 2021
Distillery Therapeutics

VEGF-A gene editing therapy to treat wet AMD

DISEASE CATEGORY: Ophthalmic disease INDICATION: Age-related macular degeneration (AMD) A CRISPR-Cas9-based lentiviral vector gene therapy targeting VEGF-A could prevent wet AMD. In a mouse model of laser-induced wet AMD, pretreatment with the gene therapy injected subretinally...
BioCentury | Dec 22, 2020
Deals

Dec. 21-23 Deals Quick Takes: Cytokinetics regains European rights to heart failure program; plus Boehringer-Epizyme, Vertex-Skyhawk, Lilly-Prevail, GSK-Sosei Heptares, ImmunityBio-NantKwest and more

Cytokinetics regains European rights from Servier to heart failure programCytokinetics Inc. (NASDAQ:CYTK) regained European rights to heart failure treatment omecamtiv mecarbil from Servier. The deal termination comes a month after Amgen Inc. (NASDAQ:AMGN) returned its...
BioCentury | Dec 19, 2020
Politics, Policy & Law

COVID-19 mAb developers with ties to China excluded from Warp Speed

The Trump administration’s America First policies, especially its reluctance to support life sciences companies with ties to China, may be slowing the development of medicines that could treat or prevent COVID-19. Two biotechs focused on...
BioCentury | Dec 11, 2020
Finance

AbCellera valuation tops $15B as 2020’s IPO class nears completion

As 2020’s record-setting run of biotech IPOs nears its end, Canadian mAb developer AbCellera rode enthusiasm for its COVID-19 treatment to one of the year’s biggest offerings, then nearly tripled its value in the early...
BioCentury | Dec 2, 2020
Finance

Data Byte: IPO queue picks up post-election

While IPO activity came to a brief standstill early last month in anticipation of post-election market volatility, at least eight biotechs have since lined up for a NASDAQ listing.  And the postmarket performance of Olema...
BioCentury | Dec 2, 2020
Emerging Company Profile

Sofinnova’s Papiernik, Costa and Roche alum Garibaldi carve orphan neurology play Noema out of the pharma’s assets

Five years after Sofinnova Partners’ Antoine Papiernik first connected with Roche neurology veteran George Garibaldi, the pair have teamed up with Luigi Costa to launch orphan neurology company...
BioCentury | Sep 1, 2020
Deals

Gilead deal clears path for Jounce to advance immuno-oncology programs

Via a deal with Gilead yielding $120 million in upfront cash for rights to a preclinical oncology program, Jounce will extend its cash runway into 2023 as it presses forward with a lead program on...
Items per page:
1 - 10 of 724
BioCentury | Apr 15, 2021
Emerging Company Profile

How SV-seeded Alchemab is searching for mAbs in super responders

Alchemab is mining the B cell repertoires of super responders, a strategy used for discovering potent mAbs to treat infectious diseases, and applying the same principle to difficult-to-treat cancer and...
BioCentury | Feb 2, 2021
Product Development

Feb. 2 Quick Takes: Immunovant tumbles as it pauses trial; plus BMS, Legend-J&J, Arcutis, Prothena, VBI, Travere, Concert and Adamas

Immunovant Inc. (NASDAQ:IMVT) lost 42% to $25.08 on Tuesday after announcing it was pausing trials of anti-FCRN mAb IMVT-1401 (batoclimab) due to elevated total cholesterol and LDL signals in the Phase IIb ASCEND GO-2 thyroid...
BioCentury | Jan 30, 2021
Distillery Therapeutics

Autophagy-activating gene therapy to treat recurrent HSV-2 infection

DISEASE CATEGORY: Infectious disease INDICATION: Herpes simplex virus (HSV); meningitis Gene therapies correcting ATG4A or MAP1LC3B2 mutations could treat recurrent HSV type 2 (HSV-2) meningitis in patients with the autophagy factor mutations. Autophagy activation by HSV-2...
BioCentury | Jan 29, 2021
Distillery Therapeutics

VEGF-A gene editing therapy to treat wet AMD

DISEASE CATEGORY: Ophthalmic disease INDICATION: Age-related macular degeneration (AMD) A CRISPR-Cas9-based lentiviral vector gene therapy targeting VEGF-A could prevent wet AMD. In a mouse model of laser-induced wet AMD, pretreatment with the gene therapy injected subretinally...
BioCentury | Dec 22, 2020
Deals

Dec. 21-23 Deals Quick Takes: Cytokinetics regains European rights to heart failure program; plus Boehringer-Epizyme, Vertex-Skyhawk, Lilly-Prevail, GSK-Sosei Heptares, ImmunityBio-NantKwest and more

Cytokinetics regains European rights from Servier to heart failure programCytokinetics Inc. (NASDAQ:CYTK) regained European rights to heart failure treatment omecamtiv mecarbil from Servier. The deal termination comes a month after Amgen Inc. (NASDAQ:AMGN) returned its...
BioCentury | Dec 19, 2020
Politics, Policy & Law

COVID-19 mAb developers with ties to China excluded from Warp Speed

The Trump administration’s America First policies, especially its reluctance to support life sciences companies with ties to China, may be slowing the development of medicines that could treat or prevent COVID-19. Two biotechs focused on...
BioCentury | Dec 11, 2020
Finance

AbCellera valuation tops $15B as 2020’s IPO class nears completion

As 2020’s record-setting run of biotech IPOs nears its end, Canadian mAb developer AbCellera rode enthusiasm for its COVID-19 treatment to one of the year’s biggest offerings, then nearly tripled its value in the early...
BioCentury | Dec 2, 2020
Finance

Data Byte: IPO queue picks up post-election

While IPO activity came to a brief standstill early last month in anticipation of post-election market volatility, at least eight biotechs have since lined up for a NASDAQ listing.  And the postmarket performance of Olema...
BioCentury | Dec 2, 2020
Emerging Company Profile

Sofinnova’s Papiernik, Costa and Roche alum Garibaldi carve orphan neurology play Noema out of the pharma’s assets

Five years after Sofinnova Partners’ Antoine Papiernik first connected with Roche neurology veteran George Garibaldi, the pair have teamed up with Luigi Costa to launch orphan neurology company...
BioCentury | Sep 1, 2020
Deals

Gilead deal clears path for Jounce to advance immuno-oncology programs

Via a deal with Gilead yielding $120 million in upfront cash for rights to a preclinical oncology program, Jounce will extend its cash runway into 2023 as it presses forward with a lead program on...
Items per page:
1 - 10 of 724